Literature DB >> 19201106

Bypassing melanocyte senescence by beta-catenin: a novel way to promote melanoma.

L Larue1, F Luciani, M Kumasaka, D Champeval, N Demirkan, J Bonaventure, V Delmas.   

Abstract

The Wnt/beta-catenin signaling pathway plays a key role in several cellular functions during embryonic development and adult homeostasis. The deregulation of this pathway may lead to the development of cancer, including melanoma. Deregulation of the Wnt/beta-catenin pathway occurs through either the induction/repression of, or specific mutations in, various members of this signaling pathway; this results in the stabilization of beta-catenin and its translocation from the cytoplasm to the nucleus, where it regulates transcription. Although nuclear beta-catenin is clearly involved in malignant transformation, the mechanism by which it exerts its effects remains elusive. This review focuses on the molecular and cellular mechanisms that are driven by beta-catenin and lead to melanocyte transformation. In particular, we describe how beta-catenin induces melanocyte immortalization, a novel activity of this multifunction protein. Finally, we discuss how beta-catenin-induced immortalization can cooperate with MAPKinase pathways to produce melanoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201106     DOI: 10.1016/j.patbio.2008.11.003

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  10 in total

1.  Oxidative stress-induced downregulation of glycogen synthase kinase 3 beta in fetal membranes promotes cellular senescence†.

Authors:  Narmada Lavu; Lauren Richardson; Enkhtuya Radnaa; Talar Kechichian; Rheanna Urrabaz-Garza; Samantha Sheller-Miller; Elizabeth Bonney; Ramkumar Menon
Journal:  Biol Reprod       Date:  2019-11-21       Impact factor: 4.285

Review 2.  Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression.

Authors:  Tura C Camilli; Ashani T Weeraratna
Journal:  Biochem Pharmacol       Date:  2010-03-06       Impact factor: 5.858

3.  Molecular Mechanism of β-Catenin Signaling Pathway Inactivation in ETV1-Positive Prostate Cancers.

Authors:  Sharif Morsalin; Chunshu Yang; Jinbo Fang; Sampreet Reddy; Shubhalaxmi Kayarthodi; Ed Childs; Roland Matthews; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2015-09

4.  Inhibition of melanoma cell proliferation by targeting Wnt/β-catenin pathway through Sox4 RNA interference.

Authors:  Huahua Cai; Anhong Ni; Wen Li; Jiawen Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

Review 5.  Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.

Authors:  Michael P O'Connell; Ashani T Weeraratna
Journal:  Pigment Cell Melanoma Res       Date:  2009-08-25       Impact factor: 4.693

6.  WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner.

Authors:  K Brown; P Yang; D Salvador; R Kulikauskas; H Ruohola-Baker; A M Robitaille; A J Chien; R T Moon; V Sherwood
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

7.  Wnt signalling is a bi-directional vulnerability of cancer cells.

Authors:  David J Duffy; Aleksandar Krstic; Thomas Schwarzl; Melinda Halasz; Kristiina Iljin; Dirk Fey; Bridget Haley; Jenny Whilde; Saija Haapa-Paananen; Vidal Fey; Matthias Fischer; Frank Westermann; Kai-Oliver Henrich; Steffen Bannert; Desmond G Higgins; Walter Kolch
Journal:  Oncotarget       Date:  2016-09-13

8.  β-Catenin Expression and Activation in Conjunctival Melanoma.

Authors:  Emerentienne Larivé; Michael Nicolas; Gürkan Kaya; Nicolo Riggi; Alexandre P Moulin
Journal:  Dermatopathology (Basel)       Date:  2019-06-26

9.  Wnt and related signaling pathways in melanomagenesis.

Authors:  Jesse J Keller; Randall T Moon; Andy J Chien
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

Review 10.  WNT Signaling in Melanoma.

Authors:  Anna Gajos-Michniewicz; Malgorzata Czyz
Journal:  Int J Mol Sci       Date:  2020-07-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.